The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
Abstract
The validation of surrogate endpoints has been studied by Prentice (1989, Statistics in Medicine 8, 431-440) and Freedman, Graubard, and Schatzkin (1992, Statistics in Medicine 11, 167-178). We extended their proposals in the cases where the surrogate and the final endpoints are both binary or normally distributed. Letting T and S be random variables that denote the true and surrogate endpoint, respectively, and Z be an indicator variable for treatment, Prentice's criteria are fulfilled if Z has a significant effect on T and on S, if S has a significant effect on T, and if Z has no effect on T given S. Freedman relaxed the latter criterion by estimating PE, the proportion of the effect of Z on T that is explained by S, and by requiring that the lower confidence limit of PE be larger than some proportion, say 0.5 or 0.75. This condition can only be verified if the treatment has a massively significant effect on the true endpoint, a rare situation. We argue that two other quantities must be considered in the validation of a surrogate endpoint: RE, the effect of Z on T relative to that of Z on S, and gamma Z, the association between S and T after adjustment for Z. A surrogate is said to be perfect at the individual level when there is a perfect association between the surrogate and the final endpoint after adjustment for treatment. A surrogate is said to be perfect at the population level if RE is 1. A perfect surrogate fulfills both conditions, in which case S and T are identical up to a deterministic transformation. Fieller's theorem is used for the estimation of PE, RE, and their respective confidence intervals. Logistic regression models and the global odds ratio model studied by Dale (1986, Biometrics, 42, 909-917) are used for binary endpoints. Linear models are employed for continuous endpoints. In order to be of practical value, the validation of surrogate endpoints is shown to require large numbers of observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER
LIN, D. Y., FLEMING, T. R., & DE GRUTTOLA, V. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1 · Cited by 520
A Class of Bivariate Distributions
Plackett, R. L. (1965) · Journal of the American Statistical Association · doi:10.1080/01621459.1965.10480807 · Cited by 491
Correlated binary regression using a quadratic exponential model
ZHAO, L. P., & PRENTICE, R. L. (1990) · Biometrika · doi:10.1093/biomet/77.3.642 · Cited by 483
Modelling Progression of CD4-Lymphocyte Count and Its Relationship to Survival Time
Gruttola, V. D., & Tu, X. M. (1994) · Biometrics · doi:10.2307/2533439 · Cited by 384
Families of Bivariate Distributions
Huzurbazar, V. S., & Mardia, K. V. (1973) · International Statistical Review / Revue Internationale de Statistique · doi:10.2307/1402797 · Cited by 350
Cited by
Preacher, K. J., & Kelley, K. (2011) · Psychological Methods · doi:10.1037/a0022658 · Cited by 3,060
Principal Stratification in Causal Inference
Frangakis, C. E., & Rubin, D. B. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00021.x · Cited by 1,511
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D., & Van Gaal, L. F. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 736
Lévi, F., Zidani, R., & Misset, J.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03358-8 · Cited by 701
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
Self-citationBuyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Self-citationBurzykowski, T., Buyse, M., Piccart-Gebhart, M. J., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348
Self-citationLahm, T., Douglas, I. S., Archer, S. L., Bogaard, H. J., Chesler, N. C., Haddad, F., Hemnes, A. R., Kawut, S. M., Kline, J. A., Kolb, T. M., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1160st · Cited by 343
Progression-Free Survival: Meaningful or Simply Measurable?
Booth, C. M., & Eisenhauer, E. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7571 · Cited by 324
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Self-citationEvaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
The intermediate endpoint effect in logistic and probit regression
MacKinnon, D. P., Lockwood, C. M., Brown, C. H., Wang, W., & Hoffman, J. M. (2007) · Clinical Trials · doi:10.1177/1740774507083434 · Cited by 261
Gabler, N. B., French, B., Strom, B. L., Palevsky, H. I., Taichman, D. B., Kawut, S. M., & Halpern, S. D. (2012) · Circulation · doi:10.1161/circulationaha.112.105890 · Cited by 255
Ditlevsen, S., Christensen, U., Lynch, J., Damsgaard, M. T., & Keiding, N. (2005) · Epidemiology · doi:10.1097/01.ede.0000147107.76079.07 · Cited by 246
Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-066381 · Cited by 170
Alternative clinical end points in rectal cancer—are we getting closer?
Glynne-Jones, R., Mawdsley, S., Pearce, T., & Buyse, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl173 · Cited by 88
Self-citationDeveloping retinal biomarkers of neurological disease: an analytical perspective
MacCormick, I. J., Czanner, G., & Faragher, B. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.17 · Cited by 47
Metadata
- Authors
- Buyse, M., & Molenberghs, G.
- Venue
- Biometrics
- Publisher
- JSTOR
- Published
- 1998-09
- Volume
- 54
- Issue
- 3
- Pages
- 1014
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W2011453559
- Cited by
- 425
- References
- 25
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.